Immunicum develops vaccines for prophylactic and therapeutic treatment of cancer and infectious diseases. The company's patented platform technology is sprung from years of research within the field of transplantation immunology. The unique concept of using allogeneic dendritic cells together with neuraminidase ensures an optimal activation of the immune system against any type of cancer and infectious diseases. The vaccines allow for cost effective large scale production, effective storage and transportation, and easy administration to patients in public and private health care centers.  

Immunicum was founded in 2002 and is situated in Göteborg, Sweden.